A Case Report: Patient with Advanced Ovarial Tumour and Supporting Care

Česká verze

Authors: Dagmar Brančíková ; L. Ostřížková ; M. Protivánková; O. Bednařík; Z. Mechl
Authors place of work: Interní, hematologická a onkologická klinika, FN Brno
Published in the journal: Klin Onkol 2012; 25(6): 464-467
Category: Kazuistiky

Autor deklaruje, že v souvislosti s předmětem studie nemá žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Summary

Background:
The primary aim of palliative treatment is to improve the quality of life, followed by prolongation of overall survival. The effective regimens are usually complicated by increased side effects, particularly hematologic. Under these conditions, useful treatment is difficult and less effective.

Case:
We present the case of a patient with cancer of the abdominal and pelvic cavity (the origin was likely an ovary). The patient was treated with intensive chemotherapy (15 cycles of carboplatin and paclitaxel) and supportive care (30 doses of epoetin alpha and 2 doses of 48MIU G-CSF for neutropenia G4).

Conclusion:
A good quality of life and long-term persistent complete remission (6 months) was achieved, no transfusion, no hospitalization. Overall survival was 61 months.

Key words:
supportive care –⁠ chemotherapy –⁠ erythropoietin –⁠ anaemia

Zdroje

1. Doporučení pro lečbu hematologických toxicit: Modrá kniha Česke onkologicke společnosti. In Linkos.cz [online]. Česká onkologická společnost ČLS JEP. 15. vyd., platnost od 1. 8. 2012. Brno: Masarykův onkologický ústav 2012 : 173–180. Dostupné z: http://www.linkos.cz/files/modra-kniha/8.pdf.

2. Bokemeyer C, Aapro MS, Courdi A et al. European Organisation for Research and Treatment of Cancer(EORTC) Taskforce for the Elderly. EORTC guidelines for use of erythropoietic proteins in anaemic patiens with cancer: 2006 update. Eur J Cancer 2007; 43(2): 258–270. Epub 2006 Dec 19.

3. Aapro M, Jelkmann W, Constantinescu SN et al. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012; 106(7): 1249–1258. doi: 10.1038/bjc.2012.42. Epub 2012 Mar 6.

4. Kuderer NM, Dale DC, Crawford J et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25(21): 3158–3167.